Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisTreatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literatureTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisTeriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherenceSurvey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical AutoinjectorsUpdated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims dataSingle-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.Effects of Specialty Pharmacy Care on Health Outcomes in Multiple SclerosisDeterminants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCEAssessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patientsPersistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort.Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon betaCompliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon βPatient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosisImproving patient-physician dialog: commentary on the results of the MS Choices survey.Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management programAdherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV studyThe real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment.Hospitalization rates and discharge status in multiple sclerosisHealth insurance affects the use of disease-modifying therapy in multiple sclerosis.ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.Facilitating medication adherence in patients with multiple sclerosis.An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: a longitudinal, observational study in routine UK clinical practice.Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis.Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis.
P2860
Q22252598-E5E4E485-25C0-4A4D-BAFE-9862C72E2A17Q27015089-81659151-3CCC-450B-AAFD-7A367DCD6C92Q28066677-4845F2BD-F3A9-49D3-9E70-1DE8DF312B30Q28081876-C8309B59-C8DC-4D86-A384-4F5D8CB1657BQ30830291-DA3584E0-F863-4665-A107-96075EFE1ABEQ30834523-8A51C046-CB24-4F9E-ACB6-EF272382794DQ30839407-BFDBFC49-2FC9-4E74-9C47-4C22B327AE1CQ33572798-FCA3B857-7F37-4DA5-91DC-23B7F5ACAF2AQ33610126-C6CAAF0E-ABD5-4721-B6A1-81A504982111Q33638157-17AAE99D-A9BA-4885-B6BC-47A7D2E048B6Q33692801-A0D8FD1A-4542-471C-ADEC-C82A2D3E1A44Q33764067-963D3378-F9BA-486E-9859-B6A600570A09Q33878804-2DF9C35A-7D06-4256-8905-B916B1B26BB4Q34473419-8422F124-93CF-48AB-AFD6-7039FFDB405FQ34558986-9C1511FE-2145-40D9-AA9D-0201FFCC3CD3Q35007948-D5264E63-B31B-4582-8514-F3E9CFD8F32AQ35091777-5DC046C1-E8CF-49E0-953C-A7EC01A1FE71Q35103997-34562C34-2ECB-4835-8356-B55D6A7DE7D4Q35659134-54E1BBDE-A71F-41AB-B2C8-CB5F42D9B4F0Q35674845-27DBB3FD-3CCA-4B4D-BA00-280DDF6B9ADCQ35780959-B8CF4136-6261-4CB6-9C1C-6CC91C56F848Q35784295-FBE23D93-F923-4FB3-8EBD-0BE3096D3363Q35948187-9D053E99-ABC2-44EA-A92F-0337452FC21CQ36125599-B5BB7CC3-02A7-42EC-9BA9-93C2750416E1Q36182036-66D0BA94-8384-440A-9272-49936E0A87D6Q36223650-DFC16944-1A15-453A-9A25-B625169C6A2EQ36393288-E0D9DBBF-B956-4416-AF44-58C3B6A8C6B7Q36595213-5A140BD2-3009-4DFF-9D37-3514C0846613Q36698871-84579461-4079-468D-9015-044E43387671Q36861884-F533086A-82AF-4796-B86C-6DAB2EDFD0A3Q36882707-17015F42-2922-48E4-9592-0609C58F76ACQ37158954-33CF739A-07EB-4928-BE87-7090872DBEE6Q37320927-D1C8EA34-E5BC-4582-94C1-5F91FE4677C8Q37442437-9917C760-2DA3-4559-B1CF-1036213075B9Q37573148-EB686EBB-C8AD-4086-B99F-5367B978049EQ37601305-08D993F9-7C68-4F94-9FC3-CA620EC61CD2Q37668556-3584B2E8-AB24-458B-9418-071D04390CF8Q37682836-F0970946-3B93-4DAA-829B-69A979D969BAQ37684523-87F53E00-93BA-44BA-BD5C-C89620D283BFQ37987991-4693817C-2246-418C-A218-C1193B86D321
P2860
Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Impact of adherence to disease ...... ients with multiple sclerosis.
@en
Impact of adherence to disease ...... ients with multiple sclerosis.
@nl
type
label
Impact of adherence to disease ...... ients with multiple sclerosis.
@en
Impact of adherence to disease ...... ients with multiple sclerosis.
@nl
prefLabel
Impact of adherence to disease ...... ients with multiple sclerosis.
@en
Impact of adherence to disease ...... ients with multiple sclerosis.
@nl
P2093
P2860
P1433
P1476
Impact of adherence to disease ...... ients with multiple sclerosis.
@en
P2093
Hiangkiat Tan
Judith J Stephenson
Siddhesh Kamat
Sonalee Agarwal
P2860
P2888
P356
10.1007/S12325-010-0093-7
P407
P577
2010-12-06T00:00:00Z